Osmotica Pharmaceutical Announces the Commercial Launch of Its KHEDEZLA (desvenlafaxine) Extended-Release Tablets, 50 mg and 100 mg

Published: Sep 27, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MARIETTA, Ga.--(BUSINESS WIRE)--Osmotica Pharmaceutical Corp. today announced the commercial launch of KHEDEZLA (desvenlafaxine) Extended-release (ER) Tablets, 50 mg and 100 mg. Osmotica’s commercial partner Par Pharmaceutical began shipment of the product today. The sales and marketing of KHEDEZLA is supported by Par Pharmaceutical’s Strativa Pharmaceuticals proprietary division. Osmotica received approval for its New Drug Application (NDA) for KHEDEZLA ER Tablets from the U.S. Food and Drug Administration pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act in July 2013. KHEDEZLA is indicated for the treatment of major depressive disorder (MDD).

Help employers find you! Check out all the jobs and post your resume.

Back to news